Catal­ent drops $350M to ex­pand In­di­ana site that in­cludes Mod­er­na-ded­i­cat­ed line

Bloom­ing­ton, IN, is the home of In­di­ana Hoosiers bas­ket­ball – and the cen­ter of Catal­ent’s bi­o­log­ics drug sub­stance man­u­fac­tur­ing op­er­a­tions. And while the uni­ver­si­ty’s for­ward Trayce Jack­son-Davis might be leav­ing town ear­ly to de­clare for the NBA Draft, the CD­MO has made it clear that it isn’t go­ing any­where.

On Thurs­day, Catal­ent an­nounced a mul­ti-year, $350 mil­lion in­vest­ment at the Bloom­ing­ton site to ex­pand drug sub­stance and prod­uct man­u­fac­tur­ing. The ad­di­tions will in­clude new biore­ac­tors, sy­ringe fill­ing lines and lyophiliza­tion ca­pac­i­ty, as well as au­to­mat­ed pack­ag­ing up­grades and qual­i­ty con­trol labs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER